Maravai LifeSciences Sees Unusually Large Options Volume (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) saw unusually large options trading activity on Wednesday. Traders acquired 1,002 put options on the stock. This represents an increase of 1,791% compared to the average daily volume of 53 put options.

Maravai LifeSciences Stock Performance

NASDAQ:MRVI traded down $0.16 on Friday, reaching $2.73. 1,186,867 shares of the company's stock were exchanged, compared to its average volume of 2,286,955. The company has a debt-to-equity ratio of 0.60, a current ratio of 5.96 and a quick ratio of 5.17. The firm has a market cap of $695.22 million, a price-to-earnings ratio of -2.39 and a beta of 0.28. Maravai LifeSciences has a 52 week low of $1.67 and a 52 week high of $10.03. The stock has a fifty day simple moving average of $2.28 and a 200-day simple moving average of $3.09.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01). The business had revenue of $46.85 million for the quarter, compared to the consensus estimate of $44.01 million. Maravai LifeSciences had a negative return on equity of 12.91% and a negative net margin of 67.14%. The company's revenue was down 26.9% compared to the same quarter last year. As a group, sell-side analysts predict that Maravai LifeSciences will post -0.24 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Stifel Nicolaus set a $5.00 price objective on shares of Maravai LifeSciences in a research report on Friday, March 21st. UBS Group dropped their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a research report on Friday, March 21st. Craig Hallum dropped their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Morgan Stanley dropped their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Tuesday, March 25th. Finally, Robert W. Baird lowered their price objective on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $6.64.

Hedge Funds Weigh In On Maravai LifeSciences

A number of large investors have recently modified their holdings of the company. Performa Ltd US LLC boosted its position in shares of Maravai LifeSciences by 614.3% in the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock valued at $27,000 after acquiring an additional 4,300 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Maravai LifeSciences by 12.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 70,828 shares of the company's stock valued at $387,000 after purchasing an additional 7,946 shares during the last quarter. VELA Investment Management LLC grew its stake in Maravai LifeSciences by 5.6% in the 1st quarter. VELA Investment Management LLC now owns 156,334 shares of the company's stock worth $345,000 after buying an additional 8,222 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Maravai LifeSciences by 3,541.4% in the 4th quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company's stock worth $56,000 after buying an additional 9,916 shares in the last quarter. Finally, MetLife Investment Management LLC grew its stake in Maravai LifeSciences by 15.7% in the 4th quarter. MetLife Investment Management LLC now owns 74,904 shares of the company's stock worth $408,000 after buying an additional 10,168 shares in the last quarter. 50.25% of the stock is currently owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.